Last reviewed · How we verify

SVT-15652

Salvat · Phase 3 active Small molecule

SVT-15652 is a small molecule that targets the cardiac sodium channel.

SVT-15652 is a small molecule that targets the cardiac sodium channel. Used for Atrial fibrillation for stroke prevention.

At a glance

Generic nameSVT-15652
Also known asSVT-15652 Otic Solution
SponsorSalvat
Drug classsodium channel blocker
Targetcardiac sodium channel
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

By inhibiting the cardiac sodium channel, SVT-15652 is expected to reduce the frequency of abnormal heart rhythms, such as atrial fibrillation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results